Researchers study drug for Alzheimer's stem cell treatment

04/24/2006 | United Press International

U.S. researchers say Axonyx's Posiphen was found to improve the ability of transplanted human neuronal stem cells to change into neurons in biotech mice. They say the Phase I trial drug appears to suppress the amyloid precursor protein, allowing new neurons to be produced in the brain, a critical development toward a stem cell therapy for Alzheimer's.

View Full Article in:

United Press International

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC